Investors

Corporate Profile

Contineum Therapeutics (Nasdaq: CTNM)  is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for inflammatory and fibrotic diseases with significant unmet need.  PIPE-791, an LPA1 receptor antagonist, is in clinical development for idiopathic pulmonary fibrosis and chronic pain.  PIPE-307 is a selective inhibitor of the M1 receptor in clinical development by Johnson & Johnson for major depressive disorder.

Upcoming Events

Coming soon.

Past Events

Investor Contact

3565 General Atomics Court, Suite 200
San Diego, CA 92121

Direct: +1.858.333.5280